|
GB2148299B
(en)
|
1983-09-01 |
1988-01-06 |
Hybritech Inc |
Antibody compositions of therapeutic agents having an extended serum half-life
|
|
US4908431A
(en)
|
1986-01-22 |
1990-03-13 |
Temple University-Of The Commonwealth System Of Higher Education |
Monoclonal antibodies to human kininogen and methods of preparing same
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク，インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
|
US5846534A
(en)
|
1988-02-12 |
1998-12-08 |
British Technology Group Limited |
Antibodies to the antigen campath-1
|
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US5976531A
(en)
|
1990-04-19 |
1999-11-02 |
The Dow Chemical Company |
Composite antibodies of human subgroup IV light chain capable of binding to tag-72
|
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
CA2082160C
(en)
|
1991-03-06 |
2003-05-06 |
Mary M. Bendig |
Humanised and chimeric monoclonal antibodies
|
|
US5795965A
(en)
|
1991-04-25 |
1998-08-18 |
Chugai Seiyaku Kabushiki Kaisha |
Reshaped human to human interleukin-6 receptor
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US6042828A
(en)
|
1992-09-07 |
2000-03-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Humanized antibodies to ganglioside GM2
|
|
EP0627932B1
(en)
|
1992-11-04 |
2002-05-08 |
City Of Hope |
Antibody construct
|
|
US5441734A
(en)
|
1993-02-25 |
1995-08-15 |
Schering Corporation |
Metal-interferon-alpha crystals
|
|
US5840299A
(en)
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
|
PT699237E
(pt)
|
1994-03-17 |
2003-07-31 |
Merck Patent Gmbh |
Fvs de cadeia anti-egfr e anticorpos anti-egfr
|
|
DE69523857T2
(de)
|
1994-09-16 |
2002-06-13 |
Merck Patent Gmbh |
Immunokonjugate
|
|
US20020164788A1
(en)
|
1994-12-02 |
2002-11-07 |
The Wellcome Foundation Limited |
Humanized antibodies to CD38
|
|
US5977322A
(en)
|
1995-06-14 |
1999-11-02 |
The Regents Of The University Of California |
High affinity human antibodies to tumor antigens
|
|
ES2176484T3
(es)
|
1995-08-18 |
2002-12-01 |
Morphosys Ag |
Bancos de proteinas/(poli)peptidos.
|
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
|
AU719513B2
(en)
|
1996-05-04 |
2000-05-11 |
Astrazeneca Ab |
Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
|
|
US6417337B1
(en)
|
1996-10-31 |
2002-07-09 |
The Dow Chemical Company |
High affinity humanized anti-CEA monoclonal antibodies
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
GB9709421D0
(en)
|
1997-05-10 |
1997-07-02 |
Zeneca Ltd |
Chemical compounds
|
|
ES2297889T3
(es)
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
Derivados de hormona de crecimiento y proteinas relacionadas.
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
BR9915548A
(pt)
|
1998-10-16 |
2001-08-14 |
Biogen Inc |
Proteìnas de fusão de interferon-beta e usos
|
|
DK1137789T3
(da)
|
1998-12-09 |
2010-11-08 |
Phyton Holdings Llc |
Fremgangsmåde til fremstilling af et glycoprotein med glycosylering af human type
|
|
US7223397B1
(en)
|
1999-01-07 |
2007-05-29 |
Research Development Foundation |
Potentiation of anti-CD38-Immunotoxin cytotoxicity
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
EP1161266A4
(en)
|
1999-03-12 |
2007-09-19 |
Univ Georgetown |
Matriptase, a serine protease and its applications
|
|
US7312318B2
(en)
|
2002-03-01 |
2007-12-25 |
Immunomedics, Inc. |
Internalizing anti-CD74 antibodies and methods of use
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US7063845B2
(en)
|
2000-04-28 |
2006-06-20 |
Gemini Science, Inc. |
Human anti-CD40 antibodies
|
|
US7521047B2
(en)
|
2000-05-12 |
2009-04-21 |
Gpc Biotech Ag |
Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
|
|
JP2003535908A
(ja)
|
2000-06-22 |
2003-12-02 |
アイデック ファーマスーティカルズ コーポレイション |
二重特異性融合タンパク及び標的細胞を殺傷するエフェクター細胞を増強するための使用方法
|
|
ES2252261T3
(es)
|
2000-06-28 |
2006-05-16 |
Glycofi, Inc. |
Metodos para producir glicoproteinas modificadas.
|
|
EP1174440A1
(en)
|
2000-07-19 |
2002-01-23 |
U-BISys B.V. |
A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
ME00502B
(me)
|
2001-01-05 |
2011-10-10 |
Amgen Fremont Inc |
Antitjela za insulinu sličan receptor faktora i rasta
|
|
FR2823764B1
(fr)
|
2001-04-24 |
2003-12-12 |
Genodyssee |
Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
|
|
US20020193569A1
(en)
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
EP1409544B1
(en)
|
2001-07-03 |
2009-06-17 |
Genentech, Inc. |
Human dr4 antibodies and uses thereof
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
AR035119A1
(es)
|
2001-08-16 |
2004-04-14 |
Lilly Co Eli |
Anticuerpos humanos antagonistas anti-htnfsf13b
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
IL162835A0
(en)
|
2002-01-09 |
2005-11-20 |
Medarex Inc |
Human monoclonal antibodies against cd30
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
CA2491017A1
(en)
|
2002-07-03 |
2004-01-15 |
Immunogen, Inc. |
Antibodies to non-shed muc1 and muc16, and uses thereof
|
|
DE60332358D1
(de)
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
AU2003267700A1
(en)
|
2002-09-09 |
2004-03-29 |
Nautilus Biotech |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
KR20050107435A
(ko)
|
2003-02-18 |
2005-11-11 |
메르크 파텐트 게엠베하 |
개선된 특성의 인터페론 알파 뮤테인의 융합 단백질
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
WO2005044307A2
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Methods of therapy for b cell-related cancers
|
|
AU2005235811B2
(en)
|
2004-02-06 |
2011-11-03 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
|
KR20140066259A
(ko)
|
2004-02-06 |
2014-05-30 |
모르포시스 아게 |
항-ｃｄ３８ 인간 항체 및 그의 용도
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US7273608B2
(en)
|
2004-03-11 |
2007-09-25 |
City Of Hope |
Humanized anti-CEA T84.66 antibody and uses thereof
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
AU2005259221B2
(en)
|
2004-07-01 |
2011-02-10 |
Innate Pharma |
Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
|
|
WO2006044643A2
(en)
|
2004-10-15 |
2006-04-27 |
Seattle Genetics, Inc. |
Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
JP5225069B2
(ja)
*
|
2005-03-23 |
2013-07-03 |
ゲンマブ エー／エス |
多発性骨髄腫の治療のためのｃｄ３８に対する抗体
|
|
TW200745162A
(en)
*
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
|
MX2007014889A
(es)
|
2005-05-26 |
2008-02-19 |
Schering Corp |
Fusion de interferon-inmunoglobulina g.
|
|
AU2006263331B2
(en)
|
2005-06-29 |
2012-02-16 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Recombinant interferon alpha2 (IFNalpha2) mutants
|
|
EP2397498A3
(en)
|
2005-07-18 |
2013-11-27 |
Amgen, Inc |
Human anti-B7RP1 neutralizing antibodies
|
|
NZ566395A
(en)
|
2005-09-26 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to CD70
|
|
US20070190068A1
(en)
|
2005-10-10 |
2007-08-16 |
Richard Hart |
uPAR-binding molecule-drug conjugates and uses thereof
|
|
CA2625681C
(en)
|
2005-10-12 |
2016-08-02 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
|
|
EP1954720A1
(en)
|
2005-10-31 |
2008-08-13 |
The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health |
Antibodies and immunotoxins that target human glycoprotein nmb
|
|
GB0525214D0
(en)
|
2005-12-12 |
2006-01-18 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
CN101045156B
(zh)
|
2006-03-29 |
2012-05-02 |
刘宏利 |
特异靶向性药物及其用途
|
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
|
FR2905375A1
(fr)
|
2006-08-29 |
2008-03-07 |
Biomethodes Sa |
Variants ameliores de l'interferon alpha humain
|
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
WO2008037257A2
(en)
|
2006-09-26 |
2008-04-03 |
Genmab A/S |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
WO2008124086A2
(en)
|
2007-04-05 |
2008-10-16 |
President And Fellows Of Harvard College |
Chimeric activators: quantitatively designed protein therapeutics and uses thereof
|
|
CL2008001334A1
(es)
|
2007-05-08 |
2008-09-22 |
Genentech Inc |
Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
|
|
EP2152751A1
(en)
|
2007-05-31 |
2010-02-17 |
Genmab A/S |
Fusion or linked proteins with extended half life
|
|
EP2187971A2
(en)
|
2007-08-01 |
2010-05-26 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
A fold-back diabody diphtheria toxin immunotoxin and methods of use
|
|
US20090076249A1
(en)
|
2007-09-19 |
2009-03-19 |
Michel De Weers |
Antibodies against CD38 for treatment of multiple myeloma
|
|
CN101868246A
(zh)
|
2007-09-21 |
2010-10-20 |
加利福尼亚大学董事会 |
被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
|
|
WO2009073975A1
(en)
|
2007-12-10 |
2009-06-18 |
National Research Council Of Canada |
Production of recombinant interferon proteins
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
US9221914B2
(en)
|
2007-12-26 |
2015-12-29 |
Biotest Ag |
Agents targeting CD138 and uses thereof
|
|
EP2313435A4
(en)
|
2008-07-01 |
2012-08-08 |
Aveo Pharmaceuticals Inc |
FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
|
|
EP2433967A3
(en)
|
2009-03-16 |
2013-05-01 |
Cephalon Australia Pty Ltd |
Humanised antibodies with anti-tumour activity
|
|
SMT202000031T1
(it)
|
2010-06-09 |
2020-03-13 |
Genmab As |
Anticorpi contro cd38 umano
|
|
US8909257B2
(en)
|
2010-06-19 |
2014-12-09 |
Qualcomm Incorporated |
Positioning protocol conveyance
|
|
DK2621531T3
(en)
*
|
2010-09-27 |
2017-02-27 |
Morphosys Ag |
ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
|
|
US9505826B2
(en)
|
2010-12-22 |
2016-11-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
EP3559049B1
(en)
*
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
ES2694180T3
(es)
|
2012-01-20 |
2018-12-18 |
Vib Vzw |
Citocinas de haz alfa-helicoidal mutantes dirigidas
|
|
PT2822575T
(pt)
|
2012-03-03 |
2020-07-02 |
Immungene Inc |
Moléculas de fusão anticorpos-mutante de interferão modificadas
|
|
US9783589B2
(en)
|
2012-08-13 |
2017-10-10 |
Immungene Inc |
Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
|
|
EP2948427A2
(de)
|
2013-01-25 |
2015-12-02 |
Covestro Deutschland AG |
Sicherheitselement mit volumenhologramm und druckmerkmal
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
BR112015027313A2
(pt)
*
|
2013-04-29 |
2017-09-26 |
Teva Pharmaceuticals Australia Pty Ltd |
anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
US10544199B2
(en)
*
|
2014-10-29 |
2020-01-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Interferon alpha 2B variants
|